肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
10期
690-692
,共3页
癌%非小细胞肺癌%血管抑制素类%药物疗法,联合
癌%非小細胞肺癌%血管抑製素類%藥物療法,聯閤
암%비소세포폐암%혈관억제소류%약물요법,연합
Carcinoma%non-small-cell lung%Angiostatins%Drug therapy,combination
目的 评价重组人血管内皮抑制素(商品名:恩度)联合吉西他滨加顺铂(GP)方案治疗晚期非小细胞肺癌( NSCLC)的疗效和安全性.方法 采用非随机同期对照的方法,以接受重组人血管内皮抑制素联合化疗的NSCLC患者32例为试验组,单纯GP方案化疗者40例为对照组.比较两组有效率(RR)、临床受益率( CBR)、肿瘤进展时间(TTP)、生活质量(QOL)及安全性.结果 试验组和对照组的总RR分别为40.6％(13/32)和20.0％(8/40),差异无统计学意义(x2=3.66,P=0.07),总CBR分别为68.8％(22/32)和42.5％(17/40),差异有统计学意义(x2 =4.93,P=0.034),总的中位TTP分别为5.2个月和3.9个月,差异有统计学意义(P=0.042).试验组与对照组不良反应的发生率差异无统计学意义(P＞0.05).结论 重组人血管内皮抑制素联合GP方案能明显提高晚期NSCLC的RR、CBR及中位TTP,安全性好,具有较好的临床应用前景.
目的 評價重組人血管內皮抑製素(商品名:恩度)聯閤吉西他濱加順鉑(GP)方案治療晚期非小細胞肺癌( NSCLC)的療效和安全性.方法 採用非隨機同期對照的方法,以接受重組人血管內皮抑製素聯閤化療的NSCLC患者32例為試驗組,單純GP方案化療者40例為對照組.比較兩組有效率(RR)、臨床受益率( CBR)、腫瘤進展時間(TTP)、生活質量(QOL)及安全性.結果 試驗組和對照組的總RR分彆為40.6％(13/32)和20.0％(8/40),差異無統計學意義(x2=3.66,P=0.07),總CBR分彆為68.8％(22/32)和42.5％(17/40),差異有統計學意義(x2 =4.93,P=0.034),總的中位TTP分彆為5.2箇月和3.9箇月,差異有統計學意義(P=0.042).試驗組與對照組不良反應的髮生率差異無統計學意義(P＞0.05).結論 重組人血管內皮抑製素聯閤GP方案能明顯提高晚期NSCLC的RR、CBR及中位TTP,安全性好,具有較好的臨床應用前景.
목적 평개중조인혈관내피억제소(상품명:은도)연합길서타빈가순박(GP)방안치료만기비소세포폐암( NSCLC)적료효화안전성.방법 채용비수궤동기대조적방법,이접수중조인혈관내피억제소연합화료적NSCLC환자32례위시험조,단순GP방안화료자40례위대조조.비교량조유효솔(RR)、림상수익솔( CBR)、종류진전시간(TTP)、생활질량(QOL)급안전성.결과 시험조화대조조적총RR분별위40.6％(13/32)화20.0％(8/40),차이무통계학의의(x2=3.66,P=0.07),총CBR분별위68.8％(22/32)화42.5％(17/40),차이유통계학의의(x2 =4.93,P=0.034),총적중위TTP분별위5.2개월화3.9개월,차이유통계학의의(P=0.042).시험조여대조조불량반응적발생솔차이무통계학의의(P＞0.05).결론 중조인혈관내피억제소연합GP방안능명현제고만기NSCLC적RR、CBR급중위TTP,안전성호,구유교호적림상응용전경.
Objective To evaluate the efficacy and security of combined recombinant human endostatin with GP chemotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC).Methods Non- randomized concurrent control was used.32 patients were treated by recombinant human endostatin combined with chemotherapy as test group,40 patients of control group only received chemotherapy.The response rate (RR),the clinical benefit rate (CBR) and the time to progression (TTP) were observed.Results The total RR in two groups were 40.6 ％ and 20.0 ％ (x2 =3.66,P =0.07).The total CBR were 68.8 ％ and 42.5 ％ (x2 =4.93,P =0.034).The total time to progression were 5.2 months and 3.9 months (P =0.042).Incidence of adverse reactions of experimental group and control group was no significant difference.Conclusion Combined recombinant human endostatin and chemotherapy can improve the curative effect (RR,CBR and TTP) of advanced NSCLC.
